Vivos Therapeutics, an emerging leader in the treatment of obstructive sleep apnea (“OSA”), is positioned to capitalize on the growing global OSA market, projected to reach $13.24 billion by 2027. The company’s unique approach is…
Sleep apnea devices market growth also driven by the current pandemic which has made it exponentially more difficult for patients to seek treatment for their condition Registered with the FDA as a Specification Developer, Vivos…
Vivos Therapeutics’ proprietary Vivos System(R) leverages a multidisciplinary treatment protocol comprised of comfortable oral devices and other therapies as needed. Over the course of treatment, typically ranging from 18 to 24 months, most patients experience…
Estimates suggest obstructive sleep apnea (“OSA”) costs the US economy $150 billion annually Medicare beneficiaries with obstructive sleep apnea cost taxpayers $19,566 per year Company’s oral appliances have shown to be effective in over 15,000…
Vivos Therapeutics, an emerging global leader in the treatment of obstructive sleep apnea (“OSA”), has developed a proprietary system that holds the potential to relieve OSA symptoms in 18-24 months. A recent article further discussing…
Vivos Therapeutics, an emerging global leader in the treatment of obstructive sleep apnea (“OSA”), has developed a groundbreaking remedy that holds the potential to be a possible solution for the life-threatening condition. A recent article…
Vivos Therapeutics, an emerging global leader in the treatment of obstructive sleep apnea (“OSA”), is on a mission to eliminate OSA using its revolutionary Vivos System(R), a clinical breakthrough in the treatment of sleep apnea…
Obstructive sleep apnea affects millions of people of all ages. It is estimated that OSA costs the US economy $165B annually. The Vivos technology represents the first non-surgical, non-invasive and cost-effective solution for the estimated…